Dogwood Therapeutics, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Dogwood reported Q2 2026 results with 217 patients enrolled in its lead Halneuron Phase 2b chemotherapy-induced neuropathy trial, expecting top-line results in fall 2026. The company announced a worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100M to Dogwood and CVR holders. Cash position of $9.6M provides runway through Q4 2026 trial readout; however, a $9.2M non-cash IPR&D impairment charge was recorded due to stock price decline.
Why this rating
Phase 2b trial progress and $100M partnership are meaningful for $8.1M-cap company; impairment non-cash; near-term catalyst (fall 2026 data) significant but execution risk remains.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.